Table 2.

Clinical and procedural characteristics, primary and secondary outcomes of the total group.

Pt	Age/sex	Clinic risk	Comorbidity	Treatment	Contraindication for ST	Precedural complication	Major bleeding	Minor bleeding	Clinical success	Mortality
1	53/F	Massive	CAD	PMT	Recent major surgery	+, hematoma in the puncture site	–	+, hematoma	+ *	Alive
2	38/M	Massive	None	PMT	Trauma, recent major surgery	–	–	–	+ *	Alive
3	33/F	Massive	None	PMT	Recent major surgery	–	–	–	+ *	Alive
4	51/F	Massive	CAD	PMT	Recent major surgery	–	–	–	–	Dead, in-hospital mortality due to advanced malignancy
5	61/M	Massive	Malignancy	PMT	Recent major surgery	–	–	–	+ *	Dead, 1 month, after discharge, PE-related
6	73/F	Massive	CAD, DM, malignancy	PMT	CNS neoplasm	–	–	–	+ *	Alive
7	59/F	Submassive	ITP	PMT	Recent major surgery	–	–	+, hematoma	+ *	Alive
8	25/M	Submassive	None	PMT	Recent major surgery	–	–	–	+ *	Alive
9	73/F	Submassive	UC	PMT	Recent GİS bleeding	–	–	–	+ *	Alive
10	53/M	Submassive	Malignancy	MT	CNS neoplasm	–	–	+, ecchimosis	+ *	Alive
11	58/F	Submassive	HT	MT	Recent ischaemic stroke	–	–	–	+ *	Alive
12	52/F	Submassive	CRF	PMT	Recent major surgery	–	–	–	+ *	Alive
13	34/F	Submassive	None	PMT	Recent major surgery	–	+, hematoma, 3 units ES transfusion	–	+ *	Alive
14	65/F	Submassive	Malignancy	MT	Central nervus system neoplasm	+, hematoma in the puncture site	–	+, hematoma	+ *	Dead, in-hospital PE-related
15	85/F	Submassive	HT, aritmi	MT	Refractory hypertension	–	–	–	+ *	Alive

Pt – patient number; F – female; M – male; N – no; Y – yes.

^*Hemodynamic stabilization achieved in the first 24 hours.

ST – systemic thrombolysis; CAD – coronary artey disease; DM – diabetes mellitus; ITP – immun thrombocytopenic purpura; UC – ulcerative colitis; CRF – chronic renal failure; HT – hypertension; PMT – pharmacomechanical thrombolysis; T – thrombolytic therapy, alteplase; MT – mechanical thrombectomy, thrombus aspiration; ES – erythrocyte suspension; CNS – central nervous system.